The LLY vs Novo Nordisk 2026 debate has shifted. Eli Lilly has pulled ahead in the GLP-1 race while Novo Nordisk works to defend its semaglutide franchise.
For long-term investors, the question is which company has the pipeline, margins, and regulatory positioning to compound returns over the next three to five years.
This breakdown walks through market share, oral GLP-1 readouts, valuation, compounding pharmacy risk, and the thesis for each name.
GLP-1 Market Share: Mounjaro and Zepbound Pull Ahead
Eli Lilly entered 2026 with momentum. Combined sales of Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) reached roughly 36 billion dollars in 2025, ahead of Novo's combined Ozempic and Wegovy haul.
Wegovy is still a strong brand, with Novo reporting it now drives a meaningful share of new US obesity prescriptions after price cuts and broader access.
The directional read: Lilly is gaining share, especially in obesity, while Novo fights to keep semaglutide volume growing.
Oral GLP-1 Race: Orforglipron vs Amycretin
The next leg of the story is oral therapy. Pills are easier to manufacture and ship than weekly injections, so whoever lands a competitive oral GLP-1 first could reset the market again.
Orforglipron (Eli Lilly)
Orforglipron is a once-daily oral small-molecule GLP-1. Across multiple Phase 3 readouts in 2025, it hit primary endpoints in obesity and type 2 diabetes, prompting Lilly to plan global regulatory submissions.
Amycretin (Novo Nordisk)
Amycretin is a dual GLP-1 and amylin agonist with injectable and oral formulations. Phase 2 data showed strong weight loss and glycemic effects, and Novo has guided to a broad Phase 3 program in 2026 across obesity and diabetes.
That puts amycretin behind orforglipron on timeline, but the dual mechanism could matter if late-stage data hold up.
You can track LLY and NVO side by side, plus thematic exposure through XLV and XBI, on the Gotrade US stocks hub. Build a watchlist before the next pipeline catalyst.
Valuation Comparison: Forward P/E, Growth, and Margins
Valuation is where the two stocks diverge most sharply in 2026. The market has rewarded Lilly's pipeline lead with a richer multiple, while Novo trades at a meaningful discount after its 2025 reset.
Forward P/E and Growth
Lilly typically trades at a premium forward earnings multiple versus large-cap pharma, reflecting expectations of sustained Mounjaro and Zepbound growth and the orforglipron option value.
Novo trades at a more moderate multiple, closer to the broader pharma group, which lowers the bar for upside if amycretin and Wegovy execution hold.
Operating Margin
Both run high operating margins by pharma standards. Novo has historically held a structural margin edge from its insulin scale, while Lilly's incretin franchise is lifting its margin profile as volume scales.
Pull the latest forward P/E and margin figures from filings before sizing a position. Multiples can compress quickly when sentiment shifts.
Compounding Pharmacy Risk and US Regulatory Outlook
Compounded GLP-1s have been a real headwind for both companies. With FDA-listed shortages of tirzepatide and semaglutide resolved, compounders have been required to wind down mass production.
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would block large outsourcing facilities from compounding these molecules from bulk API. The proposal is in a public comment period.
If finalized, branded prescription volume should benefit since compounded options become harder to source legally. Telehealth players like Hims and Hers have already been adjusting their GLP-1 strategies.
Investment Thesis: 3 to 5 Year Horizon
The honest answer is that neither name is a slam dunk at current prices. Each fits a different style of investor.
The LLY Case
Lilly is the higher-conviction pipeline story. Tirzepatide is winning share, orforglipron is the most advanced oral GLP-1, and the company is investing heavily in manufacturing capacity. The risk is the premium multiple, which leaves less room for execution slips.
The NVO Case
Novo is the value reset trade. Wegovy is still a major brand, amycretin is a credible next-generation asset, and the lower multiple gives a bigger margin of safety if 2026 results stabilize. The risk is that share losses to tirzepatide continue and pricing pressure compounds.
Conclusion
LLY versus Novo Nordisk in 2026 is a contrast between a richly priced category leader and a discounted incumbent rebuilding momentum. Both can work in a portfolio, but they reward different temperaments and time horizons.
Per CNBC reporting on Novo Nordisk's Q1 2026 earnings, Wegovy momentum is real but the share gap with Lilly remains. Watching prescription trends, oral pipeline catalysts, and the 503B rule outcome over the next two quarters should clarify which thesis is winning.
Open a Gotrade account to trade LLY, NVO, and the broader healthcare and biotech complex with fractional shares from your phone, on your timeline.
FAQ
Is LLY or NVO a better stock to buy in 2026?
LLY has the stronger pipeline and momentum, while NVO offers a lower multiple and reset expectations, so the answer depends on your risk tolerance.
What is the main difference between Mounjaro and Ozempic?
Mounjaro uses tirzepatide, a dual GIP and GLP-1 agonist, while Ozempic uses semaglutide, a GLP-1-only agonist.
When could orforglipron be approved?
Eli Lilly has guided to global regulatory submissions for obesity following positive Phase 3 readouts, but specific approval timing depends on each regulator.
Will the FDA ban compounded GLP-1s?
The FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which is in a public comment period in 2026.
How can I get exposure to GLP-1 stocks beyond LLY and NVO?
Healthcare and biotech ETFs like XLV and XBI offer broader exposure, while individual names like Hims and Hers tie to the telehealth angle.
